Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 24585896)

1.

Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.

Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P, Johnson M, Chadwick D, Nitsch D, Jones R, Sabin CA, Post FA; UK Collaborative HIV Cohort Study Steering Committee.

J Infect Dis. 2014 Aug 1;210(3):363-73. doi: 10.1093/infdis/jiu107. Epub 2014 Feb 28.

2.

Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up.

Laprise C, Baril JG, Dufresne S, Trottier H.

Clin Infect Dis. 2013 Feb;56(4):567-75. doi: 10.1093/cid/cis937. Epub 2012 Nov 9.

3.

Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.

Cao Y, Han Y, Xie J, Cui Q, Zhang L, Li Y, Li Y, Song X, Zhu T, Li T.

BMC Infect Dis. 2013 Jul 1;13:301. doi: 10.1186/1471-2334-13-301.

4.

Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.

Yoshino M, Yagura H, Kushida H, Yonemoto H, Bando H, Ogawa Y, Yajima K, Kasai D, Taniguchi T, Watanabe D, Nishida Y, Kuwahara T, Uehira T, Shirasaka T.

J Infect Chemother. 2012 Apr;18(2):169-74. doi: 10.1007/s10156-011-0310-6. Epub 2011 Oct 4.

PMID:
21968965
5.

Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.

Pradat P, Le Pogam MA, Okon JB, Trolliet P, Miailhes P, Brochier C, Maynard M, Bailly F, Zoulim F, Cotte L.

J Viral Hepat. 2013 Sep;20(9):650-7. doi: 10.1111/jvh.12088. Epub 2013 Mar 5.

PMID:
23910650
6.

Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.

Gupta SK, Anderson AM, Ebrahimi R, Fralich T, Graham H, Scharen-Guivel V, Flaherty JF, Fortin C, Kalayjian RC, Rachlis A, Wyatt CM.

PLoS One. 2014 Mar 20;9(3):e92717. doi: 10.1371/journal.pone.0092717. eCollection 2014.

7.

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.

Judd A, Boyd KL, Stöhr W, Dunn D, Butler K, Lyall H, Sharland M, Shingadia D, Riordan A, Gibb DM.

AIDS. 2010 Feb 20;24(4):525-34. doi: 10.1097/QAD.0b013e3283333680.

PMID:
20139752
8.

Renal function with use of a tenofovir-containing initial antiretroviral regimen.

Gallant JE, Moore RD.

AIDS. 2009 Sep 24;23(15):1971-5. doi: 10.1097/QAD.0b013e32832c96e9.

9.

Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.

Tanaka H, Arai M, Tomoda Y, Wada T, Yago K, Satoh M.

J Pharm Pharm Sci. 2013;16(3):405-13.

10.

Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.

Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM; Partners PrEP Study Team.

JAMA Intern Med. 2015 Feb;175(2):246-54. doi: 10.1001/jamainternmed.2014.6786.

PMID:
25531343
11.

Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.

Pujari SN, Smith C, Makane A, Youle M, Johnson M, Bele V, Joshi K, Dabhade D, Bhagani S.

BMC Infect Dis. 2014 Mar 29;14:173. doi: 10.1186/1471-2334-14-173.

12.

The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.

Young J, Wang Q, Fux CA, Bernasconi E, Furrer H, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC; Swiss HIV Cohort Study.

HIV Med. 2014 Sep;15(8):505-10. doi: 10.1111/hiv.12149. Epub 2014 Mar 18.

PMID:
24641488
13.

Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.

Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, Gerstoft J, Obel N.

Scand J Infect Dis. 2012 Sep;44(9):689-96. doi: 10.3109/00365548.2012.673730. Epub 2012 Jun 10.

PMID:
22680981
14.

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.

Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S; California Collaborative Treatment Group 578 Team.

J Infect Dis. 2008 Jan 1;197(1):102-8. doi: 10.1086/524061.

15.

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A; AI266073 Study Group.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf.

PMID:
19357529
16.

Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.

Winston J, Chonchol M, Gallant J, Durr J, Canada RB, Liu H, Martin P, Patel K, Hindman J, Piontkowsky D.

HIV Clin Trials. 2014 Nov-Dec;15(6):231-45. doi: 10.1310/hct1506-231.

PMID:
25433663
17.

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.

Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, Palma P, Bernardi S.

BMC Infect Dis. 2012 Jan 23;12:18. doi: 10.1186/1471-2334-12-18.

18.

Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.

Woratanarat K, Kanjanabuch T, Suankratay C.

J Med Assoc Thai. 2013 Apr;96(4):432-9.

PMID:
23691697
19.

Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).

De Beaudrap P, Diallo MB, Landman R, Guèye NF, Ndiaye I, Diouf A, Kane CT, Etard JF, Girard PM, Sow PS, Delaporte E; ANRS 1215 Study Group.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1221-7. doi: 10.1089/aid.2009.0261. Epub 2010 Sep 21.

PMID:
20854202
20.

The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.

Wikman P, Safont P, Del Palacio M, Moreno A, Moreno S, Casado JL.

Nephrol Dial Transplant. 2013 Aug;28(8):2073-81. doi: 10.1093/ndt/gft210. Epub 2013 Jun 5.

PMID:
23739150
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk